Figures
Abstract
The objective of this study was to evaluate the chemopreventive effect of a novel flavonoid, ampelopsin (AMP) on the growth and metastasis of prostate cancer cells. AMP showed the more potent activity in inhibiting the proliferation of androgen-sensitive LNCaP and, to less extent, androgen-independent PC-3 human prostate cancer cell lines in vitro, primarily by induction of apoptosis associated with down-regulation of bcl-2. On the other hand, AMP showed much less activity in inhibiting the proliferation of normal prostate epithelial cells than that of prostate cancer cell lines. AMP also inhibited the migration and invasion of PC-3 cells in vitro associated with down-regulation of CXCR4 expression. In the animal study using an orthotopic prostate tumor model, AMP (150 and 300 mg/kg body weight) inhibited the growth of PC-3 tumors and lymph node and lung metastases in a dose-dependent manner. Compared to the control mice, mice treated with AMP at 300 mg/kg BW had reduced final tumor weight by 49.2% (P<0.05), lymph node metastases by 54.5% (P = 0.3) and lung metastases by 93% (P<0.05), but had no apparent alteration on food intake or body weight. The in vivo anti-growth and anti-metastasis activities of AMP were associated with induction of apoptosis and inhibition of proliferation of prostate cancer cells, reduction of prostate tumor angiogenesis, and reduction of CXCR4 expression. Our results provide supporting evidence to warrant further investigation to develop AMP as a novel efficacious and safe candidate agent against progression and metastasis of prostate cancer.
Citation: Ni F, Gong Y, Li L, Abdolmaleky HM, Zhou J-R (2012) Flavonoid Ampelopsin Inhibits the Growth and Metastasis of Prostate Cancer In Vitro and in Mice. PLoS ONE 7(6): e38802. https://doi.org/10.1371/journal.pone.0038802
Editor: Rakesh K. Srivastava, The University of Kansas Medical Center, United States of America
Received: December 27, 2011; Accepted: May 10, 2012; Published: June 5, 2012
Copyright: © 2012 Ni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Foundation of Chinese Ministry of Health & United Fujian Provincial Health and Education (WKJ2008-2-60), Foundation of Fujian Provincial Department of Science & Technology (2011Y0015) and Scientific Research Foundation of Exploitation on Industrial Technology of Fujian Development and Reform Commission (2008-762) to FN, and Department of Defense (PC073988) and NCI/NIH (R21 CA133865) to JRZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the menuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Prostate cancer is the most common invasive malignancy and the second-leading cause of cancer death in men in the U.S. It is estimated that 241,740 new cases of prostate cancer would be diagnosed and about 28,170 men would die of prostate cancer in the United States in 2012 [1]. Current therapeutic modalities for prostate cancer usually have variable effectiveness, develop metastasis and drug-resistance, and have high toxicity to normal tissues. Therefore, the searching for effective regimens with moderate adverse effects for the chemopreventive intervention of prostate cancer remains the top priority in prostate cancer research.
Bioactive components in botanicals and herbal medicines may provide effective and safe candidates for chemoprevention and/or therapy of cancer. Classical Chinese medical texts contain extensive empirical records of botanical therapies used to treat patients with cancer and cancer-related systems. However, most of these candidate botanical formulas are recommended based on clinical observations only. Moreover, these clinical observations were almost always from uncontrolled, observational studies or anecdotal case reports. Until very recently, there has been limited effort to develop preclinical, mechanistic, scientific evaluation of botanical herbal products as a prerequisite for human clinical studies.
The Chinese herb Ampelopsis grossedentata is widely distributed in South China and is used to treat cold and tinea corporis. It contains a rich resource of phytochemicals with ampelopsin (AMP, (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one) the major flavonoid. AMP is also called dihydromyricetin and has a similar structure to myricetin (3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone), a naturally occurring flavonoid found in grapes, berries, fruits, vegetables, herbs and other plants with certain anti-cancer activities. As the major bioactive constituent of Ampelopsis grossedentata, AMP was shown to be mainly responsible for the reported biological activities, including hypoglycemic [2], anti-oxidative [3], [4] and hepatoprotective [4], [5] activities. AMP also enhanced the chemokinesis and chemotaxis effects of neutrophilic granulocytes and monocytes [6].
AMP was shown to possess certain anti-cancer activities. AMP inhibited the growth [7] and invasion of melanoma cells in vitro [8], [9], and inhibited metastasis of melanoma tumor in vivo [8], [9]. AMP inhibited the growth of lung tumors in vivo by inhibiting proliferation [10]. AMP had anti-angiogenesis activity by inhibiting the secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) from human hepatocellular carcinoma cells in vitro and also inhibited the growth of human hepatocellular carcinoma in mice [11]. AMP also reversed multidrug resistance in leukemia cells in vitro in part via decreasing the expression of p-glycoprotein [12]. On the other hand, the effect of AMP on the growth and progression of prostate cancer has not been studied.
The objectives of this study were to systematically evaluate AMP as a potential chemopreventive and therapeutic candidate against prostate cancer progression by using both in vitro and in vivo systems, and to elucidate the underlying cellular and molecular mechanisms of AMP actions. Our results provided experimental evidence to support the future development of AMP as an effective and safe candidate agent for the prevention and/or therapy of prostate cancer.
Results
Effects of AMP, total flavonoid extract (TFE) and myricetin on the proliferation of prostate cancer cell lines and normal prostate epithelial cells (PrEC) in vitro
We first compared the activity among AMP, TFE and myricetin in inhibiting the proliferation of prostate cancer cell lines and PrEC. The AMP purity analysis by high performance liquid chromatography (HPLC) showed that AMP purity was about 95%, and the representative HPLC chromatogram was shown in Fig. S1. TFE concentrations were calculated based on its AMP level, thus the difference of activity between TFE and AMP is attributed to other phytochemicals in TFE. As shown in Fig. 1 (A, B, C), AMP and TFE showed the similar activities in inhibiting the proliferation of prostate cancer cells or normal prostate cells, suggesting that AMP is the major bioactive flavonoid in TFE. AMP or TFE inhibited the proliferation of LNCaP cell line at the IC50's about 25 µM (Fig. 1A), and that of PC-3 cell line at the IC50's about 60 µM (Fig. 1B). On the other hand, AMP or TFE showed much less activity in inhibiting the proliferation of normal prostate epithelial cells than that of prostate cancer cell lines (Fig. 1C), suggesting that AMP or TFE may have moderate/minimal side effect.
A: The dose-dependent effects of AMP, TFE and myricetin on the proliferation of androgen-sensitive LNCaP cell line; B: The dose-dependent effects of AMP, TFE and myricetin on the proliferation of androgen-independent PC-3 cell line; C: The dose-dependent effects of AMP, TFE and myricetin on the proliferation of PrEC. Values are means±SEM of at least three independent experiments, each in triplicates.
On contrast, myricetin showed more potent activity in inhibiting the proliferation of PrEC than that of LNCaP or PC-3. Although myricetin inhibited the growth of prostate cancer cell lines at the IC50s >60 µM (Fig. 1A, 1B), it inhibited the growth PrEC cells at the IC50 about 35 µM (Fig 1C). Because of the potent anti-cancer activity and minimal side effect of AMP, it was used for further evaluation.
Effects of AMP on cell cycle progression of prostate cancer cell lines in vitro
AMP at 25 and 50 µM significantly increased the fraction of LNCaP cells at S phase from 20% to 28% (P<0.05) and 74% (P<0.001), respectively (Fig. 2B). On the other hand, AMP at 25 and 50 µM increased the fraction of PC-3 cells at S phase from 22% to 28% (P>0.05) and 34% (P<0.05), respectively (Fig. 2E), and at G2/M phases from 17% to 23% (P<0.05) and 24% (P<0.05), respectively (Fig. 2F).
A, B, and C: The dose-dependent effect of AMP on the distribution of LNCaP cells at G1 (A), S (B) and G2/M (C) phases; D, E, and F: The dose-dependent effect of AMP on the distribution of PC-3 cells at G1 (D), S (E) and G2/M (F) phases. Values are mean±SEM of three independent experiments, each in duplicates. Within the panel, the value with a letter is significantly different from that of the control, a, p<0.05; b, p<0.01; c, p<0.001.
Several cell cycle related biomarkers, such as cell division cycle 2 (CDC2), CDC25c, cyclin B1 and cyclin-dependent kinase 2 (CDK2), were determined by Western blot analysis. AMP significantly downregulated CDK2 protein level in LNCaP cells (Fig. 3B, 3C) and CDC2 protein level in PC-3 cells (Fig. 3E, 3F), but not other cell cycle related biomarkers.
A and D: The dose-dependent effect of AMP on the proportion of DNA fragmentation (sub-G0), a marker of apoptosis, in LNCaP (A) and PC-3 (D) cell lines; B and E: The representative Western blot images showing the effects of AMP on protein levels of cell cycle progression and apoptosis related biomarkers in LNCaP (B) and PC-3 (E) cell lines; C and F: Quantitation of significantly altered protein levels in LNCaP (C) and PC-3 (F) cell lines by densitometry after normalization to β-actin. The images for quantitation were from at least two independent experiments. Values are mean±SEM of three independent experiments, each in duplicates. Within the panel, the value with a letter is significantly different from that of the control, a, p<0.05; b, p<0.01; c, p<0.001.
Effects of AMP on apoptosis induction of prostate cancer cell lines in vitro
AMP also significantly increased prostate cancer cell DNA fragmentation, a hallmark for apoptosis. AMP at 25 and 50 µM significantly induced DNA fragmentation of LNCaP cells by 15-fold (P<0.001) and 70-fold (P<0.001) respectively (Fig. 3A), and PC-3 cells by 86% (P<0.05) and 270% (P<0.001) respectively (Fig. 3D), compared with the corresponding controls. LNCaP cells were further treated with AMP at 25 and 50 µM and apoptosis related molecular biomarkers were determined by Western blot analysis. AMP induced apoptosis of LNCaP and PC-3 cells associated with downregulation of Bcl-2 (Fig. 3B, 3C, 3E, 3F).
The apoptosis induction effect of AMP on PC-3 cell line was further confirmed using the Annexin V-PI flow cytometry assay. AMP showed dose- and time- dependent effects on inducing PC-3 cell apoptosis (Fig. S2).
Effects of AMP on migration and invasion of PC-3 cells and downregulation of CXCR4 protein level in vitro
PC-3 cell line was used to evaluate the effect of AMP on prostate cancer cell migration and invasion. AMP at 25 and 50 µM significantly inhibited PC-3 cell migration by 26% (P<0.05) and 63% (P<0.01), respectively (Fig. 4A), and invasion by 27% (P<0.05) and 45% (P<0.01), respectively (Fig. 4B). The inhibitory effect of AMP on PC-3 cell migration and invasion was associated with downregulation of CXCR4 protein level (Fig. 4C, 4D), an important biomarker for cancer cell invasion and metastasis. Under the experimental condition (16-hr treatment), AMP did not cause PC-3 cell cytotoxicity, as measured by the trypan blue assay (Fig. S3). It suggests that the observed anti-migration and anti-invasion activities of AMP are not secondarily due to its cytotixicity.
A: The dose-dependent effect of AMP on migration of PC-3 cells; B: The dose-dependent effect of AMP on invasion of PC-3 cells; C: The dose-dependent effect of AMP on CXCR4 protein levels in PC-3 cells; D: Quantitation of CXCR4 protein levels in PC-3 cells by densitometry after normalization to β-actin. Values are mean±SEM of three independent experiments, each in duplicate. Within the panel, the value with a letter is significantly different from that of the control, a, p<0.05; b, p<0.01; c, p<0.001.
Effects of AMP on the growth and metastasis of androgen-independent PC-3 prostate tumors and modulation of tumor cell proliferation, apoptosis and CXCR4 expression and tumor angiogenesis in mice
An orthotopic PC-3 tumor animal model was used to evaluate the effect of AMP on preventing the growth and metastasis of prostate tumor. AMP inhibited both tumor growth and metastasis in vivo in a dose-dependent manner. AMP at 150 and 300 mg/kg BW reduced the final tumor weight by 28% (P>0.05) and 52% (P<0.05) respectively (Fig. 5A), inhibited lymph nodes metastases by 27% (P>0.05) and 43% (P>0.05) respectively (Fig. 5B), and inhibited lung metastases by 57% (P>0.05) and 86% (P<0.05) respectively (Fig. 5C). The representative images of lung metastases are shown in Fig. S4. On the other hand, AMP treatments did not significantly alter total food intake (Fig. 5D) or final body weight (Fig. 5E).
Values are group mean±SEM (n = 8/group). Within the panel, the value with a letter is significantly different from that of the control, a, p<0.05.
Analyses of cellular markers showed that AMP treatment significantly induced prostate cancer cell apoptosis by 200% (Fig. 6A, P<0.001), reduced prostate cancer cell proliferation by 60% (Fig. 6B, P<0.001) and inhibited prostate tumor angiogenesis by 58% (Fig. 6C, P<0.05). These results confirmed that AMP inhibited the growth of prostate tumors by inducing apoptosis, reducing proliferation, and inhibiting prostate tumor angiogenesis in vivo. The representative images of cellular biomarkers are shown in Fig. S5. The AMP treatment also reduced CXCR4 protein expression by 30% in prostate tumors (Fig. 6D, P<0.05).
Values are group mean±SEM (n = 8/group). Within the panel, the value with a letter is significantly different from that of the control, a, p<0.05; c, p<0.001.
Discussion
In the present study, we found that AMP significantly inhibited the proliferation of prostate cancer cell lines via apoptosis induction associated with downregulation of Bcl2 expression, and suppressed prostate cancer cell migration and invasion associated with downregulation of CXCR4 expression in vitro. The animal study further confirmed that AMP significantly reduced the final tumor weight associated with inducing prostate cancer cell apoptosis, inhibiting prostate cancer cell proliferation and reducing prostate tumor angiogenesis, and significantly inhibited lung metastases. On the other hand, AMP at effective doses did not show significant adverse effect on food intake or body weight. This is the first study, to the best of our knowledge, that demonstrated the inhibitory effect of AMP on the growth and metastasis of prostate cancer in vitro and in a clinically relevant orthotopic tumor model.
Cellular mechanism studies showed that AMP inhibited the proliferation of prostate cancer cells. Interestingly, AMP arrested LNCaP cells at S phase (Fig. 2B) in part via down regulation of CDK2 (Fig. 3B, 3C), a biomarker essential for the G1/S transition, whereas it arrested PC-3 cells at S and G2/M phases (Fig. 2E, 2F) associated with downregulation of CDC2 (Fig. 3E, 3F). CDC2, also known as CDK1 (cyclin dependent kinase 1), plays an important role during the cell cycle progress. CDC2 usually combines with cyclin B and regulates the S and G2/M phase progression. CDC2 has been considered as an essential molecular target for design of therapeutic anti-cancer drugs [13]. Down-regulation of CDC2 may provide an important molecular mechanism that AMP arrests cell cycle progression of PC-3 cells at S and G2/M phases. Analysis of in vivo tumor samples also confirmed that AMP inhibited PC-3 tumor growth associated with inhibition of tumor cell proliferation (Fig. 6B).
Induction of prostate cancer cell apoptosis is also an important mechanism by which AMP inhibit the growth of prostate cancer. AMP induced apoptosis of prostate cancer cells in vitro (Fig. 3A, 3D) and in vivo (Fig. 6A). Further investigation showed that induction of apoptosis was associated with down regulation of bcl-2 protein levels (Fig. 3C, 3F). Bcl-2 is an important regulator of apoptosis. Expression of bcl-2 is more frequent in high-grade tumors and metastases than in lower-grade and nonmetastatic tumors [14], [15]. Apoptosis resistance is associated with higher levels of bcl-2 [15], [16], and downregulation of bcl-2 sensitizes prostate cancer cells to undergo apoptosis [17]. Therefore, downregulation of bcl-2 could represent an important molecular mechanism by which AMP induces prostate cancer apoptosis.
Angiogenesis is a critical step in tumor growth [18]. The growth of all solid tumors depends on angiogenesis and suppression of tumor blood vessel offers a new option for the prevention and treatment of cancer [19]. Previous studies showed that AMP had anti-angiogenesis activity by inhibiting the secretion of pro-angiogenic factor VEGF and bFGF from human hepatocellular carcinoma cells in vitro [11]. In this study, we demonstrated that AMP inhibited the growth of PC-3 prostate tumor associated with inhibition of tumor angiogenesis (Fig. 6C). Although we did not measure the VEGF and bFGF levels in vivo, our results provided suggestive experimental evidence to support that one of the mechanisms by which AMP inhibits tumor growth is via inhibiting angiogenesis. Further investigation is needed to determine the underlying molecular mechanisms that AMP inhibits tumor angiogenesis.
Previous studies have shown that AMP inhibited the in vitro invasion and in vivo metastasis ability of B16 melanoma [8]. However, it has not been studied if AMP had anti-metastasis activity in prostate cancer. Our results demonstrated that AMP had potent activities in inhibiting migration and invasion of prostate cancer cells in vitro and prostate cancer metastasis in the orthotopic prostate tumor animal model associated with downregulation of CXCR4 expression. CXCR4 is involved in several diseases such as angiogenesis, metabolic and neurological disorders, rheumatoid arthritis and in different forms of metastatic cancer. CXCR4 is a critical factor in the invasiveness and proliferation of breast cancer cells [20], [21], [22] and plays a pivotal role for the growth of malignant neuronal and glial tumors [23]. CXCR4 inhibitors are suggested for the treatment of different forms of metastatic cancer [24], [25], [26]. AMP is shown to be a small molecule CXCR4 antagonist [27], [28]. Although we did not study if CXCR4 was a direct molecular target for AMP, our studies suggest that one of the molecular mechanisms by which AMP inhibits prostate cancer metastasis may be via downregulation of CXCR4 expression and function. Further investigation in applying AMP and/or its derivatives as novel anti-metastasis agents for delaying and/or preventing cancer metastasis could have significant impacts on prevention and therapy of cancer.
In conclusion, the results from this study provided critically important experimental evidence to suggest that AMP may be a novel efficacious and safe candidate agent to inhibit the growth and metastasis of prostate cancer.
Materials and Methods
Ethics statement
All procedures with animals were reviewed and approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center with the Guide for the Care and Use of Laboratory Animals.
TFE, AMP and myricetin
A proprietary extraction procedure was applied to extract TFE from Ampelopsis grossedentata with AMP content at approximately 80%. AMP was purified from TFE by preparative HPLC; and the purity was verified by analytical reverse phase HPLC. Myricetin was purchased from LKT Laboratories (St. Paul, MN). HPLC analysis was used to verify the quality of the materials. All materials were dissolved in dimethyl sulfoxide (DMSO) for cell culture studies.
Culture of prostate cancer cells, normal prostate epithelial cells and endothelial cells
Two human prostate cancer cell lines, androgen-sensitive LNCaP and androgen-independent PC-3 (American Type Culture Collection, Bethesda, MD) were used for the in vitro experiments. Human prostate cancer cell lines were maintained as monolayer cultures in DMEM medium supplemented with 10% fetal bovine serum, 2 µmol L-glutamine/mL, 100 U penicillin/mL and 100 µg streptomycin/mL in a 95% air, 5% CO2, and water-saturated atmosphere. PrEC cells were purchased from Lonza (Walkersville, MD) and cultured in PrEGM plus EGM-2 singlequotes (Lonza, Walkersville, MD) in a humidified atmosphere of 95% air and 5% CO2.
Cell growth
The effect of AMP, TFE and myricetin on the cytotoxicity of prostate cancer cells or PrEC was determined using the Cell Titer 96 Aqueous Cell Proliferation Assay (Promega, Madison, WI) as we previously described [29]. The assay determines the number of viable cells in proliferation, cytotoxicity and chemosensitivity. All assays were independently repeated at least thrice, each in triplicate, and results were confirmed by direct cell counting using a hemocytometer.
Analysis of prostate cancer cell cycle progression and DNA fragmentation
The effect of AMP treatment on cell cycle distribution of prostate cancer cell lines was determined by flow cytometry following the described procedures [30]. Cells treated with different concentration of AMP were harvested, stained with propidium iodide (at a final concentration of 50 µg/ml) and RNase (at a final concentration of 50 µg/ml), and incubated at 37°C for 30 min. Stained cells were then analyzed by FACScan (Becton Dickinson, Immunocytometry Systems, Mountview, CA) for cell cycle distribution and fragmented DNA. The experiments were independently repeated at least thrice, each in duplicate.
Annexin V and PI staining for apoptosis detection
The effect of AMP on the apoptosis of PC-3 cells was further determined by Annexin V-PI apoptosis detection kit (Chemicon International Inc, Billerica, MA) following the instruction of kit. Briefly, treated PC-3 cells were resuspended in Annexin V solution and incubated at room temperature for 15 min, PI was then added for another 5-min incubation in the dark. Apoptotic cells were analyzed by flow cytometry (Becton Dickinson, Immunocytometry Systems, Mountview, CA). The experiments were independently performed at least twice, each in duplicates.
Cancer cell migration and invasion assays
A suspension of PC3 cells (6000 cells for migration and 30000 cells for invasion) in 250 µL of serum-free DMEM with AMP or the vehicle (DMSO) was loaded into a fibronectin-coated insert for migration assay or a matrigel-coated insert for invasion assay (Biocoat, 24-well plate, 8 µm, Becton Dickinson). Each culture insert was set into a well containing 750 µL of DMEM with 5% FBS. After incubation for 16 hrs at 37°C, cells on the top of inserts were removed carefully using a cotton tip, and the cells on the underside of the insert membrane were stained with Diff-Quick Stain solutions (Dade Behring Inc., Newark, DE) and the images were captured. Cells were counted under a microscope. All assays were independently performed at least thrice, each in triplicate.
To confirm that the anti-migration and anti-invasion activities of AMP were not secondarily due to its cytotoxicity to PC-3 cells, PC-3 cells were treated with AMP (0, 25, and 50 µM) for 16 hr, and the cell numbers were measured by trypan blue exclusion assay. The experiment was independently performed at least thrice, each in duplicate.
Western blot analysis
For the in vitro study, cells were treated with different concentrations of AMP, cell lysates were prepared, and protein levels were determined by Western blot analysis following the procedures we described previously [31]. The primary antibodies used in Western blot against human antigens were as follows: cyclin B1 (1∶200), cdc2 (1∶500) and bax (1∶500) (Oncogene Research Products, Boston, MA), bcl-2 (1∶100), p21 (1∶200) and p53 (1∶500) (Santa Cruz Biotechnology, Santa Cruz, CA), CDK2 (1∶1,000) (Selleck Chemicals, Houston, TX), CXCR4 (1∶200) (R&D systems, Inc, USA), and β-actin (1∶10,000) (Merck Co., Darmstadt, Germany). For the in vivo study, tumor samples in both the control and AMP-treated groups were collected for Western blot analysis of CXCR4 protein level.
Animal study
The chemopreventive intervention activity of AMP on the growth and metastasis of PC-3 tumors was determined in an orthotopic PC-3 tumor animal model. Male severe combined immune-deficient mice (6–8-week old) were purchased from Taconic (Germantown, NY), and housed at the animal facility of Beth Israel Deaconess Medical Center in a pathogen-free environment equipped with laminar flow hoods and standard vinyl cages with air filters. After one week of acclimatization and adaptation to the AIN-93 diet, mice were randomly assigned into one of the following three experimental groups (in each group, n = 8) and pretreated via gavage daily for 2 weeks: (i) Control: the vehicle (100 µL corn oil); (ii) AMP at 150 mg/kg body weight (BW); and (iii) AMP at 300 mg/kg BW. Each mouse was then implanted orthotopically with PC-3 cells (2×106 cells/50 µL) and continued on the corresponding treatments throughout the experiment. Food intake and body weight were measured weekly. At the end of the experiment (8 weeks after PC-3 cell implantation), the mice were sacrificed; primary tumors were excised and weighed. A tumor slice from each primary tumor tissue was carefully dissected and fixed in 10% buffer-neutralized formalin, paraffin-embedded, and sectioned at 4 µm thickness for immunohistochemistry. All procedures with animals were reviewed and approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center with the Guide for the Care and Use of Laboratory Animals [32]. The animal study was repeated.
In situ detection of apoptotic index
Apoptotic cells were determined by a terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) assay (Chemicon International Inc, Billerica, MA) following our described protocols [30], [33], [34]. Six representative areas of each section without necrosis were selected and both apoptotic cells and total nuclei cells were counted under a light microscope at 400× magnification. The apoptotic index was expressed as the percentage of positive apoptotic tumor cells to total tumor cells, and the effect of treatment on apoptosis was expressed as the percentage to the control.
Immunohistochemical determination of tumor cell proliferation
The proliferation index was evaluated by calculating the proportion of cells with Ki-67 staining, following the procedures in the laboratory [31]. Both Ki-67-positive proliferating cells and total tumor cells were counted in six non-necrotic areas of each section using light microscope at 400× magnification. The proliferation index was calculated as the percentage of Ki-67-positive tumor cells to total tumor cells, and the effect of treatment on proliferation was expressed as the percentage to the control.
Immunohistochemical detection of microvessel density (MVD)
MVD was used as a marker for tumor angiogenesis and quantified by immunohistochemical staining of Factor VIII following our previously described method [30], [33], [34]. MVD was calculated by counting microvessels on 200× fields under light microscopy at six representative sites without necrosis of each section, and the effect of treatment on angiogenesis was expressed as the percentage to the control.
Statistical analysis
Results were expressed as group means±SEM and analyzed for statistical significance by analysis of variance [35] followed by Fisher's protected least-significant difference based on two-side comparisons among experimental groups using Statview 5.0 program (SAS Institute, Inc., Cary, NC). A P<0.05 was considered statistically significant.
Supporting Information
Figure S1.
The representative chromatogram showing the purity of AMP by analytical reverse phase HPLC. HPLC experimental conditions were: Instrument: Waters 2695 with auto-sampler and the photo diode array (PDA) detector; HPLC column: Phenomenox C-18 (5 µm in inner diameter, 10×250 mm); Mobile phases: A (H2O with 0.1% acetic acid) and B (acetonitrile); Gradient condition: 0–30 min, 5% B to 35% B; 30–35 min, 35% B to 95% B; 35–40 min, 95% B to 5% B; 40–45 min, 5% B; Flow rate: 1 ml/min.
https://doi.org/10.1371/journal.pone.0038802.s001
(TIF)
Figure S2.
Representative FACS histograms showing the time-dependent effect of AMP treatments (0, 20, and 50 µM) on apoptosis of PC-3 cells, as measured by the Annexin-PI flow cytometry assay.
https://doi.org/10.1371/journal.pone.0038802.s002
(TIF)
Figure S3.
The effect of AMP on PC-3 cell cytotoxicity, as measured by the trypan blue exclusion assay. The cells were treated with AMP at different concentrations for 16 hr, the same time used for migration and invasion assays. Values are mean±SEM of three independent experiments, each in duplicates. The values are statistically insignificant among groups.
https://doi.org/10.1371/journal.pone.0038802.s003
(TIF)
Figure S4.
The representative H&E images showing the inhibitory effect of AMP at 150 mg/kg body weight (BW) (B) and 300 mg/kg BW (C) on lung metastases, as compared with the control group (A).
https://doi.org/10.1371/journal.pone.0038802.s004
(TIF)
Figure S5.
The representative images showing the effects of AMP (300 mg/kg BW) on the expression of cellular biomarkers of proliferation, as measured by ki-67 staining (A), apoptosis as measured by TUNEL assay (B) and angiogenesis, as measured by Factor VIII staining for microvessel density (C).
https://doi.org/10.1371/journal.pone.0038802.s005
(TIF)
Author Contributions
Conceived and designed the experiments: FN JRZ. Performed the experiments: FN YG LL HA JRZ. Analyzed the data: FN YG JRZ. Contributed reagents/materials/analysis tools: FN JRZ. Wrote the paper: FN YG LL HA JRZ.
References
- 1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10–29.
- 2. Zhong ZX, Qin JP, Zhou GF, Chen XF (2002) [Experimental studies of hypoglycemic action on total flavone of Ampelopsis grossedentata from Guangxi]. Zhongguo Zhong Yao Za Zhi 27: 687–689.
- 3. He G, Du F, Yang W, Pei G, Zhu Y (2003) [Effects of tengcha flavonoids on scavenging oxygen free radicals and inhibiting lipid-peroxidation]. Zhong Yao Cai 26: 338–340.
- 4. Murakami T, Miyakoshi M, Araho D, Mizutani K, Kambara T, et al. (2004) Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. Biofactors 21: 175–178.
- 5. Hase K, Ohsugi M, Xiong Q, Basnet P, Kadota S, et al. (1997) Hepatoprotective effect of Hovenia dulcis THUNB. on experimental liver injuries induced by carbon tetrachloride or D-galactosamine/lipopolysaccharide. Biol Pharm Bull 20: 381–385.
- 6. Zeng S, Luo GQ, Liu DY (2006) [The chemotaxis effect of ampelopsin on the immunocytes]. Zhong Yao Cai 29: 260–262.
- 7. Liu D, Luo M (2001) [Study on inhibitory effect of ampelopsin on melanoma by serologic pharmacological method]. Zhong Yao Cai 24: 348–350.
- 8. Liu DY, Zheng HQ, Luo GQ (2003) [Effects of ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo and in vitro]. Zhongguo Zhong Yao Za Zhi 28: 957–961.
- 9. Zheng HQ, Liu DY (2003) [Anti-invasive and anti-metastatic effect of ampelopsin on melanoma]. Ai Zheng 22: 363–367.
- 10. Zeng S, Liu D, Ye Y, Wang L, Wang W (2004) [Anti-tumor effects of ampelopsin on human lung cancer GLC-82 implanted in nude mice]. Zhong Yao Cai 27: 842–845.
- 11. Luo GQ, Zeng S, Liu DY (2006) [Inhibitory effects of ampelopsin on angiogenesis]. Zhong Yao Cai 29: 146–150.
- 12. Ye J, Zheng Y, Liu D (2009) [Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 34: 761–765.
- 13. Perez de Castro I, de Carcer G, Montoya G, Malumbres M (2008) Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 8: 375–383.
- 14. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. American Journal of Pathology 148: 1567–1576.
- 15. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, et al. (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Research 55: 4438–4445.
- 16. McConkey DJ, Greene G, Pettaway CA (1996) Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Research 56: 5594–5599.
- 17. Song R, Harris LD, Pettaway CA (2010) Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway. Prostate 70: 571–583.
- 18. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1: 27–31.
- 19. Cao Y (2010) Angiogenesis: What can it offer for future medicine? Exp Cell Res 316: 1304–1308.
- 20. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, et al. (2006) The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97: 275–283.
- 21. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, et al. (2007) Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 67: 651–658.
- 22. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, et al. (2007) Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res 13: 1562–1570.
- 23. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, et al. (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100: 13513–13518.
- 24. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR (2001) Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 61: 4961–4965.
- 25. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, et al. (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62: 5930–5938.
- 26. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50–56.
- 27. Liu DY, Ye JT, Yang WH, Yan J, Zeng CH, et al. (2004) Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry. Biomed Environ Sci 17: 153–164.
- 28. Grande F, Garofalo A, Neamati N (2008) Small molecules anti-HIV therapeutics targeting CXCR4. Curr Pharm Des 14: 385–404.
- 29. Singh AV, Franke AA, Blackburn GL, Zhou JR (2006) Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 66: 1851–1858.
- 30. Zhou J-R, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, et al. (1998) The inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58: 5231–5238.
- 31. Zhou J-R, Yu L, Zerbini LF, Libermann TA, Blackburn GL (2004) Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 81: 800–806.
- 32.
NIH OLAW (2002) Institutional Animal Care and Use Committee Guidebook. In: Pitts M, editor. 2nd ed.
- 33. Zhou J-R, Gugger ET, Tanaka T, Guo Y, Blackburn GL, et al. (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129: 1628–1635.
- 34. Zhou J-R, Yu L, Zhong Y, Nassr RL, Franke AA, et al. (2002) Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. The Prostate 53: 143–153.
- 35.
Steel RGD, Torrie JH (1980) Principles and Procedures of Statistics: A Biometrical Approach. New York: McGraw-Hill book Company, Inc.